Literature DB >> 1708009

Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.

P C Sizeland1, R R Bailey, K L Lynn, R A Robson.   

Abstract

The renin-angiotensin system has been shown to have an effect on erythropoietin synthesis and hemoglobin concentration. We present a retrospective study of stable renal transplant recipients who received an angiotensin-converting enzyme (ACE) inhibitor as treatment of hypertension. Fifteen patients were eligible, with a mean hemoglobin concentration of 130.7 +/- 22.7 g/L (SD). Within 6 months of ACE-inhibitor therapy, the mean hemoglobin had fallen significantly to 110.5 +/- 23.2 g/L (p less than 0.001). No parallel change in leukocyte or platelet counts was evident. Prospective studies are needed to clarify the effect of inhibition of the renin-angiotensin system on erythropoietin synthesis and release.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1708009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.

Authors:  M C Pratt; N J Lewis-Barned; R J Walker; R R Bailey; B I Shand; J Livesey
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.

Authors:  T Yagisawa; H Toma; H Yaguchi; M Tomaru; Y Iijima; H Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 3.  Anemia in nephrotic syndrome: approach to evaluation and treatment.

Authors:  Franca Iorember; Diego Aviles
Journal:  Pediatr Nephrol       Date:  2016-12-21       Impact factor: 3.714

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.